These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 2491421)

  • 1. Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions.
    Keane WF; Anderson S; Aurell M; de Zeeuw D; Narins RG; Povar G
    Ann Intern Med; 1989 Sep; 111(6):503-16. PubMed ID: 2491421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal protection and antihypertensive drugs: current status.
    Salvetti A; Mattei P; Sudano I
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.
    Jafar TH; Schmid CH; Landa M; Giatras I; Toto R; Remuzzi G; Maschio G; Brenner BM; Kamper A; Zucchelli P; Becker G; Himmelmann A; Bannister K; Landais P; Shahinfar S; de Jong PE; de Zeeuw D; Lau J; Levey AS
    Ann Intern Med; 2001 Jul; 135(2):73-87. PubMed ID: 11453706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical use of angiotensin-converting enzyme inhibitors in patients with renal impairment.
    Elliott HL
    Blood Press Suppl; 1994; 2():31-4. PubMed ID: 8061843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antiproteinuric effects of blood pressure-lowering agents: differences between nondiabetics and diabetics.
    de Jong PE; Heeg JE; Apperloo AJ; de Zeeuw D
    J Cardiovasc Pharmacol; 1992; 19 Suppl 6():S28-32. PubMed ID: 1382162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACE inhibitors and the kidney. A risk-benefit assessment.
    Navis G; Faber HJ; de Zeeuw D; de Jong PE
    Drug Saf; 1996 Sep; 15(3):200-11. PubMed ID: 8879974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renoprotective effects of antihypertensive drugs.
    Preston RA
    Am J Hypertens; 1999 Jan; 12(1 Pt 2):19S-32S. PubMed ID: 10077416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
    Lancet; 1997 Jun; 349(9069):1857-63. PubMed ID: 9217756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-converting enzyme inhibitors in chronic renal failure.
    Opsahl JA; Abraham PA; Keane WF
    Drugs; 1990; 39 Suppl 2():23-32. PubMed ID: 2188823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal effects of angiotensin converting enzyme inhibitors: nondiabetic chronic renal disease.
    Opsahl JA; Abraham PA; Keane WF
    Cardiovasc Drugs Ther; 1990 Feb; 4(1):221-8. PubMed ID: 2285614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group.
    Giatras I; Lau J; Levey AS
    Ann Intern Med; 1997 Sep; 127(5):337-45. PubMed ID: 9273824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations for the management of special populations: renal disease in diabetes.
    Raij L
    Am J Hypertens; 2003 Nov; 16(11 Pt 2):46S-49S. PubMed ID: 14625161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive renal insufficiency: the role of angiotensin converting enzyme inhibitors.
    Savage S; Schrier RW
    Adv Intern Med; 1992; 37():85-101. PubMed ID: 1558007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibitors versus calcium antagonists in the progression of renal diseases.
    Mimran A; Ribstein J
    Am J Hypertens; 1994 Sep; 7(9 Pt 2):73S-81S. PubMed ID: 7818839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group.
    Maschio G; Alberti D; Locatelli F; Mann JF; Motolese M; Ponticelli C; Ritz E; Janin G; Zucchelli P
    J Cardiovasc Pharmacol; 1999; 33 Suppl 1():S16-20; discussion S41-3. PubMed ID: 10028949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y; Takenaka T; Nakamura T; Suzuki H
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.